In response to criticism, Amgen is reviewing privacy provisions in a patient assistance program for its pricey new cholesterol medicine which is called Repatha. Doctors and patient advocates recently complained it requires patients to surrender rights to their personal information, including personal health data. And the web site also states the information will be freely available, with few restrictions, to Amgen and unspecified third parties.